Protocol Ledger

Federal / Public Agency · Consolidated Sponsor Hub

National Cancer Center, Korea: Clinical Trials & FDA Approval Profile

National Cancer Center, Korea (Global / Institutional) sponsors 25 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 13 active protocols (9 recruiting now), 2 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)110 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for National Cancer Center, Korea
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)25
Active Pipeline (Recruiting Now)13 (9)
Completed vs Stopped Early2 / 0 (0.0%)
Median Closed Actual Enrollment110 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With National Cancer Center, Korea
Hospital Research SiteLocationShared Protocols
National Cancer CenterGoyang-si12
Asan Medical CenterSeoul3
Ajou University HospitalSuwon2

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by National Cancer Center, Korea
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT04214990Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer PatientsPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the National Cancer Center, Korea Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI